Introduction: As survival of patients with chronic myeloid leukemia (CML) is dramatically
improved over time, the prevalence of the disease is steadily increasing. At this moment, five …

Current treatment of chronic myeloid leukemia (CML) with tyrosine kinase inhibitors (TKI) is
effective in many patients, but is not curative and frequently limited by intolerance or …

Patients diagnosed with chronic myeloid leukemia (CML) and treated with BCR-ABL1
tyrosine kinase inhibitors (TKIs) have long life spans. Selection of an appropriate first-line …

With the improving knowledge of CML and its management, the goals of therapy need to be
revisited to ensure an optimal use of the BCR:: ABL1 TKIs in the frontline and later-line …

Management of chronic myeloid leukaemia (CML) has recently undergone dramatic
changes, prompting the European LeukemiaNet (ELN) to issue recommendations in 2013; …

Background Patients with newly diagnosed chronic myeloid leukemia (CML) need long-term
therapy with high efficacy and safety. Asciminib, a BCR:: ABL1 inhibitor specifically targeting …

The advent of tyrosine kinase inhibitors (TKIs) has drastically changed the treatment
outcome of chronic myeloid leukemia (CML). Imatinib was the first TKI approved, and has …

This chapter summarizes our knowledge regarding the molecular biology of chronic myeloid
leukemia (CML) and its treatment modalities using the breakpoint cluster region‐v‐abl …

Background The characteristic expression of the constitutively active oncoprotein, BCR-ABL
tyrosine kinase, in chronic myeloid leukemia (CML) was the basis for the development of …

The advent of imatinib has dramatically improved outcomes in patients with chronic
myelogenous leukemia (CML). It has become the standard of care for all patients with newly …